“…However, RSSH can be regarded as a reactive metabolite, and therefore its efficient delivery is more preferably achieved through prodrug strategies. In recent years, an array of RSSH prodrugs (also known as RSSH donors or RSSH precursors) have emerged [ [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] ], exhibiting ideal therapeutic effects against pathological processes such as ferroptosis [ 11 , 14 ], ischemia-reperfusion [ 12 , 15 ], paracetamol poisoning [ 37 ], doxorubicin-induced cardiotoxicity [ 13 ] and postoperative pain [ 36 ]. Furthermore, RSSH prodrugs are proven superior to their counterparts, such as H 2 S donors, in terms of antioxidant activity [ 36 ].…”